Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last 26.65 INR
Change Today -0.45 / -1.66%
Volume 65.4K
BFNA On Other Exchanges
Symbol
Exchange
BFNA is not on other exchanges.
As of 7:05 AM 08/4/15 All times are local (Market data is delayed by at least 15 minutes).

bafna pharmaceuticals ltd (BFNA) Snapshot

Open
28.00
Previous Close
27.10
Day High
28.00
Day Low
25.20
52 Week High
09/12/14 - 38.00
52 Week Low
08/14/14 - 22.85
Market Cap
497.2M
Average Volume 10 Days
58.4K
EPS TTM
3.57
Shares Outstanding
18.7M
EX-Date
09/19/13
P/E TM
7.5x
Dividend
--
Dividend Yield
--
Current Stock Chart for BAFNA PHARMACEUTICALS LTD (BFNA)

Related News

No related news articles were found.

bafna pharmaceuticals ltd (BFNA) Related Businessweek News

No Related Businessweek News Found

bafna pharmaceuticals ltd (BFNA) Details

Bafna Pharmaceuticals Limited manufactures and sells medicines and drugs in India and internationally. The company offers Raricap for the treatment of iron deficiency anaemia; Raricap Forte for the treatment of iron deficiency anaemia in pregnancy and lactation; Raricap L Suspension for the treatment of iron deficiency anaemia in children; Raricap Combi for the treatment of iron deficiency anaemia and calcium deficiency during pregnancy and lactation; Raricap Drops for the treatment of iron deficiency and iron deficiency anaemia in infants and toddlers; Raricap M; and Raricap Maa. It also provides contract manufacturing services. The company was founded in 1981 and is based in Chennai, India.

358 Employees
Last Reported Date: 09/1/12
Founded in 1981

bafna pharmaceuticals ltd (BFNA) Top Compensated Officers

Chairman, Managing Director, Member of Audit ...
Total Annual Compensation: 1.2M
Executive Director and Member of Stakeholders...
Total Annual Compensation: 960.0K
Compensation as of Fiscal Year 2014.

bafna pharmaceuticals ltd (BFNA) Key Developments

Bafna Pharmaceuticals Limited Reports Audited Standalone Earnings Results for the Fourth Quarter and Year Ended March 31, 2015 and Consolidated Earnings Results for the Year Ended March 31, 2015

Bafna Pharmaceuticals Limited reported audited standalone earnings results for the fourth quarter and year ended March 31, 2015 and consolidated earnings results for the year ended March 31, 2015. For the quarter, the company reported net sales/income from operations of INR 193.740 million compared to INR 392.959 million a year ago. Loss from operations before other income, finance costs and exceptional items was INR 238.202 million compared to profit from operations before other income, finance costs and exceptional items of INR 2.101 million a year ago. Loss from ordinary activities before tax was INR 261.037 million compared to INR 28.228 million a year ago. Net loss for the period was INR 227.717 million compared to INR 20.059 million a year ago. Basic and diluted loss per share was INR 12.21 compared to INR 1.08 a year ago. For the full year, on a standalone basis, the company reported net sales/income from operations of INR 1,014.094 million compared to INR 1,775.422 million a year ago. Profit from operations before other income, finance costs and exceptional items was INR 201.082 million compared to profit from operations before other income, finance costs and exceptional items of INR 128.895 million a year ago. Profit from ordinary activities before tax was INR 60.790 million compared to INR 22.251 million a year ago. Net profit for the period was INR 61.073 million compared to INR 13.361 million a year ago. Basic and diluted earnings per share before and after extraordinary items were INR 3.27 compared to INR 0.72 a year ago. For the full year, on a consolidated basis, the company reported net sales/income from operations of INR 976.749 million compared to INR 1,853.394 million a year ago. Profit from operations before other income, finance costs and exceptional items was INR 174.663 million compared to profit from operations before other income, finance costs and exceptional items of INR 138.502 million a year ago. Profit from ordinary activities before tax was INR 60.672 million compared to INR 24.912 million a year ago. Net profit for the period was INR 62.197 million compared to INR 14.444 million a year ago. Basic and diluted earnings per share before and after extraordinary items were INR 3.57 compared to INR 0.75 a year ago.

Bafna Pharmaceuticals Limited, Board Meeting, May 29, 2015

Bafna Pharmaceuticals Limited, Board Meeting, May 29, 2015. Agenda: To consider among other things, the audited financial results of the company for the year ended March 31, 2015.

Bafna Pharmaceuticals Limited to Report Fiscal Year 2015 Results on May 29, 2015

Bafna Pharmaceuticals Limited announced that they will report fiscal year 2015 results on May 29, 2015

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
BFNA:IN 26.65 INR -0.45

BFNA Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for BFNA.
View Industry Companies
 

Industry Analysis

BFNA

Industry Average

Valuation BFNA Industry Range
Price/Earnings 5.9x
Price/Sales -- Not Meaningful
Price/Book -- Not Meaningful
Price/Cash Flow 3.3x
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact BAFNA PHARMACEUTICALS LTD, please visit www.bafnapharma.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.